69579-13-1

RGH-5526 (GYKI-11679) is a new antihypertensive agent. Results show a sharp (61%) reduction in the hypothalamic Noradrenaline (NA) level 2 h after the administration of 10 mg/kg of RGH-5526, and this effect lasts for 4 to 6 h. It is demonstrated that RGH-5526 exerts a greater NA lowering effect in the hypothalamus than in the periphery. RGH-5526 does not influence the hypothalamic monoamine oxidase (MAO)-activity following prolonged treatment^[1].